Search Results - "Long, Vatana"
-
1
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Published in Clinical cancer research (15-03-2017)“…CD19, a B-cell lineage-specific marker, is highly represented in B-cell malignancies and an attractive target for therapeutic interventions. MGD011 is a CD19 x…”
Get full text
Journal Article -
2
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Published in Molecular cancer therapeutics (01-08-2018)“…We have developed MGD007 (anti-glycoprotein A33 x anti-CD3), a DART protein designed to redirect T cells to target gpA33 expressing colon cancer. The gpA33…”
Get full text
Journal Article -
3
BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact
Published in Proceedings of the National Academy of Sciences - PNAS (07-10-2008)“…We have used an inhibiting antibody to determine whether preimmune versus antigen-experienced B cells differ in their requisites for BLyS, a cytokine that…”
Get full text
Journal Article -
4
682 Antibody-mediated blockade of interleukin-10 receptor-alpha promotes the activation of immune cells from in vitro dissociated tumor samples
Published in Journal for immunotherapy of cancer (01-11-2020)“…BackgroundInterleukin-10 (IL-10) is a multifunctional cytokine that can mediate immune suppression or activation depending on the immunological context. Mouse…”
Get full text
Journal Article -
5
Abstract 1772: Immunotherapy of colorectal cancer by the T-cell targeted DART® protein MGD007: Cellular mechanisms of action
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Introduction MGD007 (glycoprotein A33 x CD3), a DART protein designed to redirect T cells to target gpA33-expressing colon cancer, is presently undergoing…”
Get full text
Journal Article -
6
Abstract 1560: Selection of a bispecific trivalent HER2 x CD137 TRIDENT format providing optimal tumor-anchored immune co-stimulation
Published in Cancer research (Chicago, Ill.) (01-07-2019)“…Introduction: CD137 (4-1BB) signaling provides co-stimulation of CD8 or NK cells following antigen or FcγR engagement, respectively. Efforts to leverage CD137…”
Get full text
Journal Article -
7
Abstract 554: Tumor-antigen 5T4-dependent activation of the CD137 costimulatory pathway by bispecific 5T4 x CD137 x CD137 TRIDENT™ molecules
Published in Cancer research (Chicago, Ill.) (01-07-2019)“…Introduction: Trophoblast glycoprotein 5T4 is expressed on the cell surface of multiple cancers yet sparingly on normal adult tissues. CD137 (4-1BB) is a…”
Get full text
Journal Article -
8
Abstract 3642: Tumor-antigen expression-dependent activation of the CD137 costimulatory pathway by bispecific DART® proteins
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Introduction: CD137 (4-1BB) is a co-stimulatory molecule expressed by activated T and NK cells that, upon interaction with its CD137 ligand, further supports…”
Get full text
Journal Article -
9
MGD011, Humanized CD19 x CD3 DART® Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-Cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-Cell Depletion in Cynomolgus Monkeys Following Once-a-Week Dosing
Published in Blood (06-12-2014)“…CD19, a lymphocyte-specific marker expressed from early B-lymphocyte development through mature memory B cells, is highly represented in B-cell malignancies,…”
Get full text
Journal Article -
10
BLyS Neutralization Ablates Primary But Not Memory B Cell Pools
Published in The FASEB journal (01-04-2008)“…The cytokine BLyS (B lymphocyte stimulator) interacts with three receptors – BR3, TACI, and BCMA – to regulate the composition and size of peripheral B cell…”
Get full text
Journal Article